



# Com.Pl.i.t DX


Personalized treatment based on tumor biology

“Your genes speak, we translate”



**GeneKor**

Committed to Biotechnological Innovation





# Com.Pl.i.t DX® Liquid

**Com.Pl.i.t DX® Liquid** analysis provides valuable information that can be used to select the optimal targeted treatment for patients. By analyzing multiple genes simultaneously, it provides a detailed fingerprint of the tumor biology, which is used by the treating physician to personalize the patient's treatment plan.

## Gene table

<b>Mutations in 12 genes</b>									
ALK	BRAF	EGFR	ERBB2	KRAS	MAP2K1	MET	NRAS	PIK3CA	RET
ROS1	TP53								


<b>3 Gene rearrangements</b>									
ALK	ROS1	RET							

- A quantity of blood is taken from the patient, as in a routine blood test
- Isolation of cancer DNA and RNA detected in the blood, also known as free circulating cancer DNA and RNA
- Ability to detect mutations at very low rates (<1%)
- Advanced Next Generation Sequencing (NGS) technology is used
- Each genetic position is read over 10,000 times by the NGS system
- Specialised software is used to analyse the data and convert raw data into information of practical use

**Com.Pl.i.t DX® Liquid is designed for patients with bowel or lung cancer.**

*Sample: Blood in 1 vial 10ml Cell-Free DNA BCT STRECK*

*10 working days*



# Com.Pl.i.t DX® Liquid Breast

The Com.Pl.i.t DX® Liquid Breast test is designed for postmenopausal women with recurrent or metastatic ER+/HER2- breast cancer and is a strong indicator of whether a patient should undergo specific targeted therapies.

## The Com.Pl.i.t DX® Liquid Breast Test is suitable for:

- Patients with breast cancer, with inoperable tumours and patients with limited or insufficient tissue biopsy material.
- Patients with multiple metastases.
- Patients on treatment or after completion of treatment. In this case, it gives an insight into the possible emergence of new targeted or resistance mutations to the therapy used.

## The test is highly recommended for targeted treatment decisions for:

- Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer after relapse to previous treatment to decide on Elacestrant treatment based on *ESR1* gene mutations.
- Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer after recurrence on previous treatment to decide on Alpelisib treatment based on *PIK3CA* gene mutations.
- Postmenopausal women with advanced or metastatic breast cancer after recurrence of previous treatment, in order to decide on treatments outside of indication or clinical trials.

# Gene Table

<b>Hotspot genes</b> (appr. 152 hotspots)	<i>AKT1</i>	<i>EGFR</i>	<i>ERBB2</i>	<i>ERBB3</i>	<i>ESR1</i>	<i>FBXW7</i>	<i>KRAS</i>	<i>PIK3CA</i>	<i>SF3B1</i>	<i>TP53</i>
--	-------------	-------------	--------------	--------------	-------------	--------------	-------------	---------------	--------------	-------------


<b>Copy number genes</b> (CNVs)	<i>CCND1</i>	<i>ERBB2</i>	<i>FGFR1</i>
------------------------------------	--------------	--------------	--------------

<b>Full length genes</b>	<i>TP53</i>		
--------------------------	-------------	--	--

- In the above gene panel, we detect mutations in the **ESR1** gene, which develop as a mechanism of resistance to hormonal therapy and are associated with approved therapy. (25-30%, based on international literature)
- We also detect the mutations in the **PIK3CA** gene, which are associated with an approved treatment. (incidence 35-45 % based on international literature)
- Finally, mutations are detected in other genes associated with experimental and off-label treatments.

Sample: Blood in 1 vial 10ml Cell-Free DNA BCT STRECK

10 working days





# Genekor Medical S.A.

52, Spaton Ave. | 15344 Gerakas Greece |

Tel. +302106032138 |

Fax.+302106032148

info@genekor.com | genekor.com

